In Vivo Pharmacology Services at JAX performs contract efficacy studies using NOD/ShiLtJ (001976) mice to evaluate new Type 1 diabetes-related therapeutics.
Type 1 diabetes (T1D), also called insulin-dependent diabetes mellitus (IDDM), is characterized by the autoimmune destruction of pancreatic beta cells. As a result, patients produce inadequate amounts of insulin. In Vivo Pharmacology Services at JAX uses NOD/ShiLtJ (001976) mice as a platform for contract preclinical efficacy studies to evaluate type I diabetes-related therapeutics.
Diabetes in NOD/ShiLtJ mice is characterized by insulitis, a leukocytic infiltration of the pancreatic islets. Marked decreases in pancreatic insulin content occur in females beginning at about 12-14 weeks of age and several weeks later in males. Consequently, plasma glucose levels increase to greater than 250 mg/dl.
A full report containing body weight and blood glucose measurements is delivered at study conclusion.